ClinicalTrials.gov
 Home    Search    Study Topics    Glossary  
 

  Full Text View  
  Tabular View  
  Contacts and Locations  
  No Study Results Posted  
  Related Studies  
A Trial Evaluating the Pharmacokinetics and Mode of Action of EndoTAG®-1 in Tumor Patients With Hepatic Metastases

This study is currently recruiting participants.
Study NCT00542048.   Last updated on November 13, 2008.   Information provided by MediGene

This Tabular View shows the required WHO registration data elements as marked by

Descriptive Information Fields
Brief Title  A Trial Evaluating the Pharmacokinetics and Mode of Action of EndoTAG®-1 in Tumor Patients With Hepatic Metastases
Official Title  An Open-Label, Uncontrolled, Phase II Trial Evaluating the Single-Dose and Steady-State Pharmacokinetics of EndoTAG®-1 and Its Effect on the Blood Supply and the Angiogenesis of Hepatic Metastases in Patients With a Carcinomatous Primary Tumor Other Than Hepatocellular (HCC), Biliary or Bile Duct Carcinoma
Brief Summary

The primary objective of study CT 4003 is to assess the behavior of EndoTAG®-1 in the body (making a so-called pharmacokinetic profile). Therefore, the course of the drug in the body is examined, i.e. the amount and speed of the drug uptake as well as the distribution and the elimination of the drug is being investigated. Further objectives of the study are to assess the effect of EndoTAG®-1 on liver metastases concerning size and blood supply measured by imaging techniques (contrast-enhanced ultrasound and magnetic resonance imaging as well as duplex sonography) and to assess the effect on blood markers which are indicators for the destruction and neoplasm of blood vessels (so-called markers of angiogenesis).

Detailed Description

Liver metastases are among the most frequent neoplasms of the liver and represent a quite uniform clinical entity regardless from which carcinoma they originate. The treatment is dependent on number and size of the hepatic lesions but still, none of the therapeutic options leads to satisfying results. The growth of tumors and metastases is dependent on blood vessels, which supply the tumors and metastases with nutrients. Liver metastases, independent from which original tumor they come from, are especially well supplied with blood. The aim of the treatment with the investigational medicinal product EndoTAG®-1 is to target the blood vessels, which supply the metastases, and destroy them. Consequently, the metastases themselves will be damaged.

Study Phase Phase II
Study Type  Interventional
Study Design  Basic Science, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Pharmacokinetics/Dynamics Study
Primary Outcome Measure  Pharmacokinetic profile [ Time Frame: Last patient out ] [ Designated as safety issue: No ]
Secondary Outcome Measure  Tumor response, Tumor perfusion, Soluble markers of angiogenesis, Pharmacodynamics, Safety [ Time Frame: Last patient out ] [ Designated as safety issue: Yes ]
Condition  Liver Cancer
Neoplasm Metastasis
Intervention  Drug: EndoTAG®-1
MEDLINE PMIDs
Links
Recruitment Information Fields
Recruitment Status  Recruiting
Enrollment  20
Start Date  November 2007
Completion Date April 2009
Eligibility Criteria 

Inclusion Criteria:

  • Unresectable hepatic metastases of a carcinomatous origin with exception of HCC, biliary or bile duct carcinoma
  • At least one measurable hepatic metastases > 20 mm in diameter (measured in MRI)
  • Last application of palliative chemotherapy (drug dependent on the primary tumor) at least 7 days ago
  • Gender: male and female (at least 6 individuals of each gender)
  • Age >= 18 years
  • Negative pregnancy test (females of childbearing potential)
  • Willingness to perform double-barrier-contraception during the study and for 6 month post study medication
  • ECOG performance status 0,1 or 2
  • Assumed life expectancy of > 3 month
  • Signed informed consent

Exclusion Criteria:

  • History of significant liver pathology (other than metastases, e.g. cirrhosis of the liver, PSC, PBC) or liver transplantation
  • Laboratory tests (hematology, chemistry) outside specific limits:
  • ANC <= 1.0 x 10^9/L
  • Platelets <= 100 x 10^9/L
  • Hb <= 9.0 g/dL (<= 5.6 mmol/L)
  • Total Bilirubin > 2.0 mg/dL
  • Serum Creatinine > 1.5 mg/dL
  • Renal insufficiency with a GFR < 60 mL/min
  • Currently ongoing taxane-containing palliative chemotherapy regimen or history of taxane administration within 4 weeks prior to study entry
  • Pregnancy or nursing status
  • Positive HIV, HBV or HCV testing
  • The patient has a contraindication for MRI or CEUS according to accepted clinical guidelines
  • Known hypersensitivity to any component of the EndoTAG®-1 formulation, gadolinium-based MR-contrast media or sulphur hexafluoride
  • Claustrophobia or history of active or significant neurological disorder and/or psychiatric disorder that would prohibit the understanding and giving of informed consent, or would interfere in the clinical and radiological evaluation of the patient during the trial
  • Concurrent treatment with other experimental drugs. Participation in another clinical trial with any investigational drug within 30 days prior to study entry
Gender Both
Ages 18 Years and older
Accepts Healthy Volunteers No
Contacts ††
Contact: Carola Adam, Dr.     0049-89-8565-2991     c.adam@medigene.com    
Contact: Matthias Karrasch, Dr.     0049-89-8565-2914     m.karrasch@medigene.com    
Location Countries  Germany
Administrative Information Fields
NCT ID  NCT00542048
Organization ID CT 4003
Secondary IDs ††
Study Sponsor  MediGene
Collaborators ††
Investigators 
Principal Investigator:     Klaus Mross, PD     Klinik für Tumorbiologie an der Albert-Ludwigs-Universität Freiburg    
Information Provided By MediGene
Verification Date November 2008
First Received Date  October 9, 2007
Last Updated Date November 13, 2008

 †    Required WHO trial registration data element.
††   WHO trial registration data element that is required only if it exists.




Links to all studies - primarily for crawlers